Pricing Log in Create free account

Candel Therapeutics, Inc. (CADL) vs Gyre Therapeutics, Inc. (GYRE)

Candel Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. Candel Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($681.8M and $678.6M). Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 10.7% against 0.00%. Candel Therapeutics, Inc. has the higher net margin (0.00% vs −13.7%) and the higher return on invested capital (0.00% vs −8.51%). Across the 17 metrics below, Gyre Therapeutics, Inc. leads on 11 and Candel Therapeutics, Inc. on 6.

Valuation

Metric CADL GYRE Biotechnology median
P/E n/m n/m 8.50
P/S 4,857.08 5.26 9.71
P/B 4.81 4.29 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 3,661.00 4.66 9.21
Earnings yield (17.22%) (3.29%) (33.15%)
Free cash flow yield (9.44%) (1.16%) (25.50%)

Profitability

Metric CADL GYRE Biotechnology median
Gross margin 0.00% 94.15% 65.16%
Operating margin 0.00% (10.53%) 0.00%
Net margin 0.00% (13.73%) 0.00%
Free cash flow margin 0.00% (6.12%) 0.00%
Return on equity (81.84%) (11.75%) (56.36%)
Return on assets (56.37%) (9.08%) (48.04%)
Return on invested capital 0.00% (8.51%) 0.00%

Growth

Metric CADL GYRE Biotechnology median
Revenue growth (TTM) 0.00% 10.72% 6.02%
EPS growth (last fiscal year) 58.62% (60.00%) 30.26%
Revenue growth, 5-year CAGR — 40.96% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL GYRE Biotechnology median
Debt to equity 0.38 0.00 0.00
Current ratio 16.09 4.26 4.72
Net debt to EBITDA 1.53 (3.74) 0.96

Dividend

Metric CADL GYRE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CADL GYRE Biotechnology median
Market cap 681.78m 678.62m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack